What is Phable?
Phable operates within the burgeoning digital health sector, offering a mobile application designed to empower individuals in managing chronic diseases. The platform facilitates 24/7 doctor intervention and leverages an intelligent care companion to assist users with lifestyle disease management. This approach positions Phable as a key player in proactive healthcare, aiming to improve patient outcomes and reduce the burden of chronic conditions through accessible technology.
How much funding has Phable raised?
Phable has raised a total of $40.1M across 4 funding rounds:
Angel/Seed
$150K
Other Financing Round
$1M
Series A
$14M
Series B
$25M
Angel/Seed (2019): $150K with participation from SOSV
Other Financing Round (2020): $1M led by Inflection Point Ventures
Series A (2021): $14M supported by Omron Ventures, Manipal Hospitals, and SOSV LLC
Series B (2022): $25M featuring Digital Horizon, Aflac Ventures, Stride Ventures, and Kalaari Capital
Key Investors in Phable
Digital Horizon
Digital Horizon is a venture capital firm that invests in technology companies. Their involvement suggests a focus on the technological innovation and scalability of Phable's platform.
Stride Ventures
Stride Ventures is an Indian venture capital firm that invests in innovative startups. Their participation indicates a strategic interest in Phable's growth within the Indian market and potentially beyond.
Kalaari Capital
Kalaari Capital is a venture capital firm focused on early-stage technology companies in India. Their investment highlights a belief in Phable's potential for significant technological advancement and market disruption.
What's next for Phable?
With substantial backing, Phable is poised for accelerated growth and enhanced service offerings. The company's strategic investments suggest a focus on expanding its technological capabilities, broadening its user base, and potentially forging new partnerships within the healthcare ecosystem. Future developments are likely to center on refining its AI-driven insights and doctor intervention protocols to further solidify its market leadership in chronic disease management.
See full Phable company page
